Stanford Children’s Health

The Pulse eNewsletter November 2025

The Pulse — Nov 2025

Happy Fall to All! We have many exciting updates to share, such as new pediatric Impella education materials for Providers and Patients/Families, a debrief of our incredibly successful first VAD Bootcamp, and many new publications and other tools. As we move into the holiday season, we reflect on our continued appreciation and thankfulness for the engagement and collaboration from all stakeholders that continue to excel our research, quality improvement, education, and advocacy efforts.

The Pulse — Nov 2025 Read More »

iDECIDE-VAD-PEDIATRIC: Development of a Decision Aid to Assist Children and Their Caregivers When Considering a Ventricular Assist Device

The iDECIDE-VAD-PEDIATRIC decision aid was developed to help families and clinicians navigate the unique challenges of pediatric ventricular assist device implantation by promoting consistent, values-based, and equitable decision-making.

iDECIDE-VAD-PEDIATRIC: Development of a Decision Aid to Assist Children and Their Caregivers When Considering a Ventricular Assist Device Read More »

The Pulse — April 2025

Let’s make 2025 our best year yet! We wrapped 2024 with the exciting announcement for the FDA expanded label of Johnson & Johnson MedTech’s Impella Support System to include treatment for certain children suffering from heart failure. Achievements like this would not be possible without the continued efforts and dedication of our ACTION centers providing care to these patients, as well as entering, cleaning, and adjudicating the data. We also continued access to the Berlin Heart Active Driver under the extended trial, and we published many new ACTION manuscripts.

The Pulse — April 2025 Read More »

The Pulse eNewsletter - February 2025

The Pulse — February 2025

Let’s make 2025 our best year yet! We wrapped 2024 with the exciting announcement for the FDA expanded label of Johnson & Johnson MedTech’s Impella Support System to include treatment for certain children suffering from heart failure. Achievements like this would not be possible without the continued efforts and dedication of our ACTION centers providing care to these patients, as well as entering, cleaning, and adjudicating the data. We also continued access to the Berlin Heart Active Driver under the extended trial, and we published many new ACTION manuscripts.

The Pulse — February 2025 Read More »